MedTrace Logo

Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases

NCT03199001 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2017-06-26

No results posted yet for this study

Summary

Fabry Disease (FD) is a rare, X-linked lysosomal storage disorder leading to left ventricular hypertrophy, myocardial fibrosis, arrhythmia and heart failure. Cardiac involvement is the leading cause of death in FD. Treatment with enzyme replacement therapy is expensive, may be poorly targeted and there are difficulties in early detection and disease monitoring. T1 mapping signal change is a potential remarkable biomarker for FD.

Fabry400 is a multicentre study aiming to understand the biology of Fabry Disease and its relationship to non-invasive multi parametric mapping by CMR.

Conditions

Sponsors & Collaborators

  • University Hospital Birmingham

    collaborator OTHER

  • University of Sydney

    collaborator OTHER

  • University College, London

    lead OTHER

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-19
Primary Completion
2018-08-19
Completion
2019-02-19

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03199001 on ClinicalTrials.gov